4D Molecular Therapeutics (NASDAQ:FDMT) Trading Up 6.2% – What’s Next?

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) was up 6.2% during mid-day trading on Monday . The company traded as high as $9.54 and last traded at $9.58. Approximately 278,901 shares were traded during trading, a decline of 63% from the average daily volume of 751,524 shares. The stock had previously closed at $9.02.

Analysts Set New Price Targets

A number of analysts have weighed in on FDMT shares. Barclays started coverage on 4D Molecular Therapeutics in a report on Wednesday, January 28th. They set an “overweight” rating and a $33.00 target price for the company. Leerink Partners restated an “outperform” rating and set a $17.00 price objective on shares of 4D Molecular Therapeutics in a research note on Friday, October 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, January 21st. Morgan Stanley upgraded shares of 4D Molecular Therapeutics from an “underweight” rating to an “equal weight” rating in a report on Friday, November 7th. Finally, Royal Bank Of Canada restated an “outperform” rating on shares of 4D Molecular Therapeutics in a report on Wednesday, January 7th. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $33.25.

4D Molecular Therapeutics Price Performance

The stock has a market cap of $553.02 million, a price-to-earnings ratio of -2.58 and a beta of 3.01. The company’s fifty day moving average price is $8.47 and its 200-day moving average price is $8.79.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Dynamic Technology Lab Private Ltd acquired a new stake in shares of 4D Molecular Therapeutics in the first quarter worth $39,000. Wexford Capital LP purchased a new stake in 4D Molecular Therapeutics in the third quarter valued at $41,000. Los Angeles Capital Management LLC acquired a new stake in 4D Molecular Therapeutics during the 2nd quarter worth about $42,000. Quadrature Capital Ltd purchased a new position in shares of 4D Molecular Therapeutics during the 2nd quarter valued at about $42,000. Finally, Farther Finance Advisors LLC lifted its holdings in shares of 4D Molecular Therapeutics by 117.4% in the 3rd quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock valued at $43,000 after buying an additional 2,674 shares during the period. Institutional investors and hedge funds own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.